Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
CMS proposes Medicare reimbursement — AOTI benefits from topical wound oxygen therapy
The US agency CMS has published a draft that would deem topical oxygen therapy medically necessary for diabetic foot ulcers after four weeks of non‑healing and provide for nationwide Medicare reimbursement. The draft enters a 45‑day comment period; a final decision is expected within a year. AOTI reports a 75% market share in this segment, expects an addressable market potential of up to $26 billion with reimbursement, and cites a near‑term revenue potential of around $400 million with existing payer coverage. » More on de.investing.com
Financials
| (EUR) | December 2025 | YoY |
|---|---|---|
| Revenue | 29.06m | - |
| Gross profit | 16.23m | - |
| Net profit | 2.03m | - |
| EBITDA | 3.81m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €178.82m |
Number of shares | 106.36m |
52-week high/low | €1.80 - €0.30 |
| Dividends | No |
Beta | 2.88 |
P/E ratio | 74.28 |
PEG ratio | 0.74 |
P/B ratio | 9.40 |
P/S ratio | 2.90 |
Company profile
| Name | AOTI INC |
| CEO | Michael Griffiths |
| Employees | 90 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
London | AOTI.L |